对接受肝动脉栓塞化疗的３３例原发性肝癌病人给予肝得健保肝，并设３０例为对照组。结果治疗组治疗前后肝功能无变化，对照组胆红素（ＢＩＬ）３天升高，２周未降至正常；丙氨酸转氨酶（ＡＬＴ）和门冬氨酸转氨酶（ＡＳＴ）３天、７天明显升高，２周降至正常；白蛋白（ＡＬＢ）７天开始下降，２周回升，但未至正常水平。表明肝得健可防止正常肝细胞损害，保护肝功能，增强对栓塞化疗的耐受性。 Forty-three patients with primary liver cancer undergoing hepatic artery embolization received hepatoprotective liver protection and 30 patients were used as control group. Results The liver function of the treatment group did not change before and after treatment. Bilirubin (BIL) increased in the control group for 3 days, but did not return to normal in 2 weeks. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 days, 7 The days were significantly elevated and fell to normal within 2 weeks; albumin (ALB) began to decline in 7 days, and recovered in 2 weeks, but not to normal levels. It was shown that Gandejian can prevent normal hepatocyte damage, protect liver function, and enhance the tolerance to embolization chemotherapy.